Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by Maxi Investments CY Ltd

Maxi Investments CY Ltd purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,100 shares of the biopharmaceutical company’s stock, valued at approximately $3,479,000.

Several other institutional investors have also recently made changes to their positions in ALNY. SCS Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $50,773,000. Silvant Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $5,456,000. WINTON GROUP Ltd bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $2,372,000. Finally, Wealthfront Advisers LLC bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $2,876,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of several research analyst reports. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday, September 8th. HC Wainwright restated a “buy” rating and issued a $455.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 21st. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a report on Monday, August 3rd. Wells Fargo & Company decreased their price target on shares of Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 14th. Finally, Oppenheimer lowered their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Four analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $364.95.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 1.6%

NASDAQ ALNY opened at $227.66 on Tuesday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $485.36. The company has a market cap of $30.46 billion, a price-to-earnings ratio of 42.32 and a beta of 0.28. The business’s fifty day moving average is $239.03 and its 200 day moving average is $290.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the company posted ($0.51) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 66.9% compared to the same quarter last year. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.